Skip to content
Buy This GLP
← Research
Evidence

GLP-1 Super Responders by Brand: What One Records Study Found

Across 135,349 people on semaglutide or tirzepatide, the share losing more than 15% ranged from 10% to 34% by brand. The study compared existing records, so differences in dose and patient characteristics may help explain the spread.

Editorial profile: Carla MedinaBuy This GLP Editorial Team8 min read
Lost more than 15% of body weightZepboundtirzepatide, weight management34%Wegovysemaglutide, weight management26%Mounjarotirzepatide, diabetes label24%Ozempicsemaglutide, diabetes label10%Observed outcomes in different patient groups.

Research on how soon people respond to a GLP-1 asks when differences show up. This analysis used records from 135,349 people treated with semaglutide or tirzepatide to describe the spread in outcomes [1]. It identified people who lost more than 15%, those who lost 5% to 15%, those with minimal weight loss, and those who gained more than 5%.

Within the four named brand groups, 40% to 42% of patients lost 5% to 15% of their starting weight. The share losing more than 15% varied more widely: 34% on Zepbound, 26% on Wegovy, 24% on Mounjaro and 10% on Ozempic [1].

The STEP trials report outcomes for the same semaglutide dose in different populations. In STEP 1, adults without diabetes on semaglutide 2.4 mg lost a mean 14.9% of body weight over 68 weeks, and 50.5% of them lost 15% or more [2]. In STEP 2, the same 2.4 mg dose in adults with type 2 diabetes produced a mean loss of 9.6% over 68 weeks [3]. At 72 weeks, the tirzepatide 15 mg group lost a mean 20.9% in SURMOUNT-1, which excluded diabetes [4]. In SURMOUNT-2, which enrolled people with type 2 diabetes, the same dose produced a mean loss of 14.7% [5].

These trials enrolled different populations. The comparisons cannot isolate the effect of diabetes status. STEP 1 counted participants who lost at least 15%, while the records study used a threshold above 15%. The studies also differed in how treatment and weight were tracked.

Compared with the moderate and minimal weight-loss groups, the largest responders were younger and more often women. Compared with the minimal weight-loss group, they were also more often White [1]. Our guide to patient characteristics in weight-loss research explains why differences in who receives treatment matter when interpreting observed outcomes. The study did not establish what caused these differences.

The paper’s results section reports that fibromyalgia and osteoarthritis were less common before treatment among the largest Zepbound responders than among matched patients with minimal weight loss. The abstract describes the conditions as more common, which conflicts with the direction reported in the results [1]. These associations describe the study groups and do not predict an individual response.

The study grouped patients by the weight change recorded in their health records. Its observational design leaves room for differences in the patients prescribed each brand and in how they used it. Our review of treatment persistence explains how refill gaps and discontinuation can affect real-world comparisons. These brand-level results cannot predict how much weight an individual will lose.

Frequently asked

Can these percentages compare how well the brands work?
The study compared existing records. The brand groups can differ in medication, dose and patient characteristics, so the percentages describe what researchers observed in those groups.
What are the odds of a large weight loss?
In this data, between 10% and 34% lost more than 15%, depending on which product they were on, while 40% to 42% landed in the 5% to 15% range across all four.
Who lost the most weight?
People who were younger, female and white were over-represented among the largest responders. The study did not establish why the groups differed.

Sources

  1. [1] Venkatakrishnan AJ, Murugadoss K, Soundararajan V (2026). Decoding the hallmarks of GLP-1RA weight-loss super-responders Biology Methods & Protocols. PMID 42147968
  2. [2] Wilding JPH, Batterham RL, Calanna S, Davies M, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity The New England Journal of Medicine. PMID 33567185
  3. [3] Davies M, Færch L, Jeppesen OK, Pakseresht A, et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Lancet. PMID 33667417
  4. [4] Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity The New England Journal of Medicine. PMID 35658024
  5. [5] Garvey WT, Frias JP, Jastreboff AM, le Roux CW, et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial Lancet. PMID 37385275

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence